Oncology research, breast cancer innovation, and biotech development by Atossa Therapeutics
Lowering mammographic breast density could cut future cancer risk, ATOSSA THERAPEUTICS, INC. asserts
ATOSSA THERAPEUTICS, INC. is intensifying its attention on mammographic breast density (MBD) as a critical factor in breast cancer prevention research. According to the company, scientific ...
Atossa Therapeutics unveils findings on complexity of Duchenne muscular dystrophy beyond protein loss
Atossa Therapeutics has put forward new research that broadens the scientific understanding of Duchenne muscular dystrophy by identifying failures in multiple biological systems, surpassing the ...
Atossa Therapeutics convenes leading experts for Endoxifen therapy virtual session
Atossa Therapeutics, Inc. recently hosted a virtual Key Opinion Leader (KOL) event titled Endoxifen Role in Breast Cancer, bringing expert focus to the development of (Z)-endoxifen for ER positive ...
Atossa Therapeutics advances research on Z-endoxifen for Duchenne muscular dystrophy
Atossa Therapeutics announced the acceptance of a manuscript for publication in Degenerative Neurological and Neuromuscular Disease detailing new research into (Z)-endoxifen as a potential therapy ...
Atossa Therapeutics brings experts together to examine endocrine therapy backbone potential
Atossa Therapeutics, Inc. will host a virtual Key Opinion Leader (KOL) event on May 19 to focus on the development of (Z)-endoxifen as a potential backbone endocrine therapy for multiple estrogen ...
ATOSSA THERAPEUTICS, INC. secures FDA rare pediatric disease status for Z-endoxifen in McCune-Albright syndrome
ATOSSA THERAPEUTICS, INC. has been granted a Rare Pediatric Disease designation by the FDA for its (Z)-endoxifen therapy targeting McCune-Albright syndrome. This regulatory milestone supports ...
FDA designations and clinical progress drive Atossa Therapeutics Q1 2026 financial report
Atossa Therapeutics released its financial results for the first quarter of 2026, detailing continued progress in its (Z)-endoxifen development programs targeting oncology and rare diseases. The ...
Atossa Therapeutics posts trial data showing reduced breast density in premenopausal women
Atossa Therapeutics, Inc. announced the publication of pivotal results from its KARISMA-Endoxifen trial, reporting significant reductions in mammographic breast density among healthy premenopausal ...
FDA awards Atossa Therapeutics rare pediatric designation for Z-endoxifen milestone
The U.S. Food and Drug Administration has granted Rare Pediatric Disease designation to (Z)-endoxifen for the treatment of McCune-Albright Syndrome, representing a significant regulatory milestone ...
Atossa Therapeutics joins industry leaders at LSINW2026 to advance cell therapy innovation momentum
Atossa Therapeutics participated in the LSINW2026 conference in Seattle this week, where leaders from across the cell therapy and pharmaceutical sectors gathered to explore the latest advances and ...
Atossa Therapeutics advances endoxifen as new option for DMD management
Atossa Therapeutics, Inc. CEO Dr. Steven Quay appeared on the Rare Connection podcast to outline the company’s exploration of endoxifen as an innovative approach to treating Duchenne muscular ...
Atossa Therapeutics, Inc. advances Z-endoxifen pipeline with key U.S. FDA designations into 2026
Atossa Therapeutics, Inc. is accelerating progress into 2026 with its Z-endoxifen clinical program in oncology and rare diseases. The company announced that it has secured important U.S. FDA ...
NCCN event spotlights Atossa Therapeutics, Inc. breast cancer innovation
Atossa Therapeutics, Inc. presented its latest developments in breast cancer research at the recent NCCN Annual Conference. Dr. Sandra Hammer, PhD, delivered a detailed poster presentation ...
ATOSSA THERAPEUTICS INC reports Q4 and full year 2025 results and unveils corporate update
ATOSSA THERAPEUTICS INC has published its financial results for the fourth quarter and the year ended December 31, 2025. The company also provided an update on recent corporate developments. ...
Atossa Therapeutics announces launch of early-stage DMD program for rare disease awareness
Atossa Therapeutics, Inc. has announced its participation in MediaplanetUSA's Rare Diseases campaign, aiming to raise awareness and support for patients and healthcare innovators tackling rare ...
Atossa Therapeutics shares clinical trial update for Z-endoxifen at MDA conference
Atossa Therapeutics delivered an oral update on its clinical trial of (Z)-endoxifen during the MDA Clinical and Scientific Conference held on March 11, 2026, in Orlando, Florida. The ...
Muscle biomarker improvement reported in dystrophic mice, Atossa Therapeutics asserts
Sandra Hammer, PhD, of Atossa Therapeutics, Inc. is set to deliver an oral presentation at the MDA Clinical and Scientific Conference. Her research outlines how (Z)-Endoxifen restores muscle ...
Atossa Therapeutics advances Z-endoxifen platform in oncology and DMD targeting molecular precision
Atossa Therapeuticsis leveraging its (Z)-endoxifen platform to bring greater molecular precision to endocrine-based therapies in oncology and Duchenne muscular dystrophy (DMD). In an in-depth ...
Atossa Therapeutics outlines Z-Endoxifen strategy for breast cancer prevention
Atossa Therapeutics, Inc. has unveiled a conceptual framework involving Z-Endoxifen and progestin-only contraception to tackle breast cancer risks. Dr. Sandra Hammer, Senior Clinical Project ...
Atossa Therapeutics to Participate in UCSF women health event
Atossa Therapeutics, Inc. is preparing to take part in the RISE UP for Breast Cancer and Women's Health conference hosted by UCSF Hospitals. This interdisciplinary event focuses on advancements in ...
Atossa Therapeutics launches research program for oral therapy in DMD
Atossa Therapeutics, Inc. has announced the initiation of a new research and development program targeting Duchenne Muscular Dystrophy (DMD) with their investigational oral therapy, endoxifen. ...
